SPC waiver may be altered on stockpiling and disclosure

European generics and biosimilars manufacturers should be allowed to stockpile within the European Union (EU) for day-one launch ahead of supplementary protection certificate (SPC) expiry, under proposed amendments to a draft SPC manufacturing waiver. Moreover, according to the amendments put forward in an opinion by a rapporteur for the European Parliament’s committee on environment, public health and food safety (ENVI), limits will also be put on the extent to which commercially-sensitive manufacturing information provided by the generics industry must be published and shared by national authorities.

European generics and biosimilars manufacturers should be allowed to stockpile within the European Union (EU) for day-one launch ahead of supplementary protection certificate (SPC) expiry, under proposed amendments to a draft SPC manufacturing waiver. Moreover, according to the amendments put forward in an opinion by a rapporteur for the European Parliament’s committee on environment, public health and food safety (ENVI), limits will also be put on the extent to which commercially-sensitive manufacturing information provided by the generics industry must be published and shared by national authorities.

The draft opinion eases industry concerns over the SPC waiver, which has been an industry goal for years but which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By 

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By 

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.

More from Generics Bulletin

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By 

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By 

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.